Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems
Tandem Diabetes Care (TNDM) has announced a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development of fully automated closed-loop insulin delivery systems. The partnership builds on their previous successful collaboration in the International Diabetes Closed Loop trials.
The collaboration combines UVA's expertise in technology-based interventions and automated insulin delivery (AID) algorithms with Tandem's market leadership in insulin delivery devices, algorithm implementation, and data management. The research will involve scientists, clinicians, and experts from both institutions, potentially leading to clinical research for Tandem's next-generation AID systems.
As part of the agreement, Tandem will provide research funding, technology, and supplies to UVA for diabetes-centered research and potential clinical studies.
Tandem Diabetes Care (TNDM) ha annunciato un accordo di collaborazione pluriennale con il University of Virginia Center for Diabetes Technology (UVA) per promuovere la ricerca e lo sviluppo di sistemi di somministrazione dell'insulina a circuito chiuso completamente automatizzati. La partnership si basa sulla loro precedente collaborazione di successo nei trial internazionali sul circuito chiuso per il diabete.
La collaborazione combina l'esperienza di UVA nelle interventi basati sulla tecnologia e negli algoritmi di somministrazione automatizzata dell'insulina (AID) con il ruolo di leadership di Tandem nel mercato dei dispositivi per la somministrazione dell'insulina, nell'implementazione degli algoritmi e nella gestione dei dati. La ricerca coinvolgerà scienziati, clinici ed esperti di entrambe le istituzioni, potenzialmente portando a ricerche cliniche per i sistemi AID di nuova generazione di Tandem.
Come parte dell'accordo, Tandem fornirà finanziamenti per la ricerca, tecnologie e forniture a UVA per la ricerca incentrata sul diabete e potenziali studi clinici.
Tandem Diabetes Care (TNDM) ha anunciado un acuerdo de colaboración de varios años con el University of Virginia Center for Diabetes Technology (UVA) para avanzar en la investigación y el desarrollo de sistemas de entrega de insulina automatizados a circuito cerrado. La asociación se basa en su colaboración exitosa anterior en los ensayos de circuito cerrado internacional sobre diabetes.
La colaboración combina la experiencia de UVA en intervenciones basadas en tecnología y en algoritmos de entrega automatizada de insulina (AID) con el liderazgo de mercado de Tandem en dispositivos de entrega de insulina, implementación de algoritmos y gestión de datos. La investigación involucrará a científicos, clínicos y expertos de ambas instituciones, lo que podría llevar a investigaciones clínicas para los sistemas AID de próxima generación de Tandem.
Como parte del acuerdo, Tandem proporcionará financiación para la investigación, tecnología y suministros a UVA para la investigación centrada en la diabetes y posibles estudios clínicos.
탄덤 다이어베티스 케어(TNDM)는 버지니아 대학교 당뇨 기술 센터(UVA)와 전자동 폐쇄형 인슐린 전달 시스템의 연구 및 개발을 증진하기 위한 다년간 협력 계약을 발표했습니다. 이 파트너십은 국제 당뇨 폐쇄형 시험에서의 이전 성공적인 협력을 기반으로 합니다.
협력은 UVA의 기술 기반 개입 및 자동 인슐린 전달(AID) 알고리듬에 대한 전문성과 탄덤의 인슐린 전달 장치, 알고리듬 구현 및 데이터 관리에 대한 시장 리더십을 결합합니다. 연구에는 두 기관의 과학자, 임상 의사 및 전문가가 참여할 것이며, 이는 탄덤의 차세대 AID 시스템을 위한 임상 연구로 이어질 가능성이 있습니다.
계약의 일환으로 탄덤은 UVA에 당뇨 중심 연구 및 잠재적 임상 연구를 위한 연구 자금, 기술 및 용품을 제공할 것입니다.
Tandem Diabetes Care (TNDM) a annoncé un accord de collaboration pluriannuel avec le Centre de technologie du diabète de l'Université de Virginie (UVA) pour faire avancer la recherche et le développement de systèmes de distribution d'insuline à boucle fermée entièrement automatisés. Le partenariat repose sur leur collaboration réussie précédente dans les essais internationaux sur les boucles fermées de diabète.
La collaboration associe l'expertise de l'UVA en interventions basées sur la technologie et en algorithmes de distribution d'insuline automatisée (AID) à la position de leader de marché de Tandem dans les dispositifs de distribution d'insuline, l'implémentation d'algorithmes et la gestion des données. La recherche impliquera des scientifiques, des cliniciens et des experts des deux institutions, ce qui pourrait conduire à des recherches cliniques pour les systèmes AID de prochaine génération de Tandem.
Dans le cadre de l'accord, Tandem fournira des financements pour la recherche, des technologies et des fournitures à l'UVA pour des recherches centrées sur le diabète et des études cliniques potentielles.
Tandem Diabetes Care (TNDM) hat eine langfristige Zusammenarbeit mit dem University of Virginia Center for Diabetes Technology (UVA) bekannt gegeben, um die Forschung und Entwicklung von vollständig automatisierten Insulinabgabesystemen mit geschlossenem Kreislauf voranzutreiben. Die Partnerschaft baut auf ihrer früheren erfolgreichen Zusammenarbeit in den internationalen Studien zu geschlossenen Kreisläufen bei Diabetes auf.
Die Zusammenarbeit vereint die Expertise von UVA in technologiebasierten Interventionen und Algorithmen zur automatisierten Insulinabgabe (AID) mit Tandems Marktführerschaft bei Insulinabgabegeräten, der Implementierung von Algorithmen und dem Datenmanagement. In die Forschung werden Wissenschaftler, Kliniker und Experten beider Institutionen einbezogen, was möglicherweise zu klinischen Studien für Tandems nächste Generation von AID-Systemen führt.
Im Rahmen der Vereinbarung wird Tandem UVA Forschungsfinanzierung, Technologie und Materialien für diabeteszentrierte Forschung und potenzielle klinische Studien bereitstellen.
- Strategic research partnership with leading diabetes technology institution
- Potential acceleration of next-generation AID systems development
- Company provides funding and resources to support research advancement
- None.
Insights
The research collaboration will rely on the UVA Center for Diabetes Technology’s groundbreaking work to improve care for patients with diabetes through technology-based interventions, and its successes in translating advanced automated insulin delivery (AID) algorithms into medical devices used around the world, as well as Tandem’s market leading expertise in insulin delivery devices, algorithm implementation, and data management.
The collaboration will expand on Tandem’s ongoing research into the advancement of automated closed-loop insulin delivery technology, and will involve scientists, clinicians, and functional experts from both institutions. Results from this collaboration may lead to clinical research to accelerate approved uses for Tandem’s next-generation AID systems.
“Our past work with UVA, including research related to our automated insulin delivery systems as part of the International Diabetes Closed Loop trials, helped contribute to life-changing products for the diabetes community,” said John Sheridan, president and chief executive officer at Tandem. “We believe this research collaboration will continue on our joint history of delivering new innovations that can further improve the lives of people living with diabetes.”
“After more than 10 years working with the Tandem team, this is an exciting new beginning for our collaboration to serve patients with diabetes,” said Marc Breton, PhD, associate director for research at the UVA Center for Diabetes Technology. “Together, we will expand our research efforts into automated insulin delivery with the goal of once more substantially enhancing care and quality of life for patients around the world.”
Tandem will provide research funding, technology, and supplies to the University of
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in
Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2 #TandemMobi and #TandemDiabetes.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at linkedin.com/company/tandemdiabetes.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things: (i) the multi-year collaboration agreement to advance research and development efforts on fully automated closed-loop systems; (ii) that the collaboration will expand upon Tandem’s ongoing research into advancing automated insulin delivery technology; (iii) that the results from this collaboration may lead to clinical research that accelerates approved uses for Tandem’s next-generation AID systems; (iv) that the collaboration will deliver new innovations that can further improve the lives and/or enhance the care of people living with diabetes; and (v) that Tandem will provide research funding, technology and supplies that will fund diabetes-centered research and potential clinical studies. These statements are subject to numerous risks and uncertainties associated with developing new products generally, including possible delays in the Company’s product development programs and/or clinical trials, possible future actions of the FDA or any other regulatory body or governmental authority, including the potential that the FDA may not agree with Tandem’s proposed pathway for regulatory approval; the potential that the collaboration agreement could be terminated; the potential that other products or technological breakthroughs for the treatment of diabetes could make Tandem’s products obsolete or less desirable. These and other risks are identified and described in greater detail under the “Risk Factors” heading of our most recent Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.
© 2025 All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107162995/en/
Media Contact:
858-255-6388
Media@tandemdiabetes.com
Investor Contact:
858-366-6900
IR@tandemdiabetes.com
Source: Tandem Diabetes Care, Inc.
FAQ
What is the purpose of TNDM's collaboration with UVA Center for Diabetes Technology?
How will the TNDM-UVA collaboration impact future product development?
What resources is TNDM providing to UVA for this research collaboration?
What is the history of collaboration between TNDM and UVA?
